MarketInOut Stock Screener Log In | Sign Up
 

Definium Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 06/23/2026 16:00
Definium Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,027.84 mln
Float108 mln
Earnings Date08/06/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

39.87
Modest upside

Relative Strength

99 / 100
Top performer

Debt / Equity

0.15
Very low leverage

ROE

-103
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Definium Therapeutics, based in New York, is a clinical-stage company focused on developing new treatments for mental health and brain-related conditions. Its most advanced drug, DT120, is currently in Phase 3 trials for generalized anxiety disorder and major depression, while a second compound, DT402, is in earlier trials targeting autism spectrum disorder. The company was previously called Mind Medicine (MindMed) before adopting its current name in January 2026.

Key Fundamentals

EPS-2.50
ROE-103
ROIC-248
ROA-73.37
EBITDA, mln-231
EV / EBITDA-9.39
EV / EBIT-9.39

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price39.87
Short Ratio5.93
Short % of Float8.71

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 52.21% 100 / 100   
1 Month 59.74% 98 / 100   
2 Months 97.49% 97 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us